SCHEMBL3537668

SCHEMBL3537668

N#Cc1ccc(-c2nc([CH]Cc3ccccc3C(N)=O)[nH]c2Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 7/20 0.45
CASP1 P29466 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
MAPK9 P45984 1/20 0.37
MAPK10 P53779 1/20 0.37
MAP2 P11137 1/20 0.35
CHEK2 O96017 1/20 0.34
RPS6KA3 P51812 1/20 0.34
FASN P49327 2/20 0.34
IRAK4 Q9NWZ3 1/20 0.34
CSF1R P07333 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
DHODH Q02127 1/20 0.33
AR P10275 1/20 0.33
IDO1 P14902 1/20 0.33
BRS3 P32247 1/20 0.32
SCN9A Q15858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4206303 0.85 CYP11B2 (0.39) PARP1CASP1ARSCN9A
SCHEMBL4212481 0.79 PARP1 (0.46) PARP1CASP1PARP2IRAK4CSF1R
SCHEMBL1921465 0.79 CXCR2 (0.42) ARIDO1
SCHEMBL3546324 0.78 F11 (0.47)
SCHEMBL4206083 0.76 PI4K2A (0.38) CSF1RSCN9A
SCHEMBL17514019 0.71 PARP1 (0.43) PARP1CASP1PARP2MAPK9MAPK10
SCHEMBL5171595 0.70 BRD4 (0.44) PARP1DHODH
SCHEMBL5173995 0.69 RAB9A (0.44) PARP1MAPK10
SCHEMBL4802582 0.68 MAPK1 (0.50) PARP1
SCHEMBL6804935 0.66 TSHR (0.47) PARP1CASP1PARP2ARIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604056-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-12-10 US disclosed
US-20120270853-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-10-25 US disclosed
US-8252830-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-08-28 US disclosed
US-7842708-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-11-30 US disclosed
US-20100022506-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-28 US disclosed
US-7626039-B2 Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-01 US disclosed
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB CO. 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270853-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 PARP1 1574/4885CASP1 457/4885PARP2 1684/4885
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 PARP1 1574/4885CASP1 457/4885PARP2 1684/4885
US-20100022506-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 PARP1 1574/4885CASP1 457/4885PARP2 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.